Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
15 Jul 2024
Historique:
accepted: 02 07 2024
received: 16 05 2024
revised: 01 07 2024
medline: 15 7 2024
pubmed: 15 7 2024
entrez: 15 7 2024
Statut: aheadofprint

Résumé

In 10/10 HLA-matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) with calcineurin-inhibitor (CNI)-based prophylaxis, T-cell epitope DP-matched and permissive mismatched donors are associated with similar overall survival (OS) while donors with non-permissive mismatches should be avoided. Younger unrelated donors are also favored over older donors. We explored outcomes associated with different combinations of DP-matching and donor age (dichotomized at 35 years) to further guide donor selection. Using a Center for International Blood and Marrow Transplant Research dataset, we categorized 10,783 patients into six groups: DP-matched/younger donor (n=1591), DP-matched/older donor (n=526), permissive-mismatched/younger donor (n=3845), permissive-mismatched/older donor (n=1184), non-permissive mismatched/younger donor (n=2659), non-permissive mismatched/older donor (n=978). We noted that younger donor age, rather than DP-matching, was associated with better OS. Younger donors with permissive mismatches were associated with improved OS compared to older matched donors. Furthermore, younger donors with non-permissive mismatches were associated with improved OS compared to older donors with permissive mismatches. Our study adds further information about the association of DP-matching and donor age with HCT outcomes. Donor age should be prioritized over DP-matching in patients undergoing 10/10 HLA-MUD with CNI prophylaxis. Among those with younger donors, permissive-mismatched or DP-matched donors are preferred over non-permissive mismatched donors.

Identifiants

pubmed: 39008717
pii: 517034
doi: 10.1182/bloodadvances.2024013677
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Rohtesh S Mehta (RS)

Fred Hutch Cancer Center, Seattle, Washington, United States.

Effie W Petersdorf (EW)

Fred Hutchinson Cancer Center, Seattle, Washington, United States.

Tao Wang (T)

CIBMTR® (Center for International Blood and Marrow Transplant Research), United States.

Stephen R Spellman (SR)

CIBMTR® (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, Minnesota, United States.

Stephanie J Lee (SJ)

Fred Hutchinson Cancer Center, Seattle, Washington, United States.

Classifications MeSH